US President Donald Trump’s aggressive tariff stance has despatched shockwaves by Indian markets, with pharma and auto shares taking a success. Trump, who’s in search of a return to energy, is contemplating imposing contemporary tariffs on prescription drugs, cars, and semiconductors. Whereas nothing is ready in stone but, if carried out, these tariffs may come into impact as early as April 2, placing vital stress on India’s export-driven sectors.
Pharma Companies within the Firing Line
Indian drug producers, together with Dr Reddy’s Laboratories, Lupin, Cipla, and Zydus, are notably susceptible. The US is an important market, accounting for almost 38 per cent of India’s pharmaceutical exports. A tariff hike would dent their margins and make Indian generics much less aggressive. At present, India imposes a 10 per cent obligation on US-made medicines, however Trump’s proposed transfer may see Indian drug exports dealing with an identical tariff for the primary time. If a ten per cent obligation is imposed, it may probably erode FY26 earnings estimates by 6.5 per cent for firms like DRL, Lupin, and Cipla.
Nonetheless, market knowledgeable Anil Singhvi believes that slapping a full 25 per cent tariff on prescription drugs is almost inconceivable. The US closely is determined by reasonably priced Indian generics, and any drastic transfer may worsen the healthcare disaster for American customers. A symbolic tariff within the vary of 5-10 per cent is extra possible, however even that would negatively influence pharma exporters. Solar Pharma and Torrent Pharma are anticipated to be comparatively insulated because of their decrease reliance on the US generics market.
Auto Sector Faces Restricted Danger
In comparison with prescription drugs, Indian automakers are in a greater place. Based on reviews, solely 0.2 per cent of India’s auto exports head to the US, limiting the direct influence of tariffs. Nonetheless, any protectionist measures by Trump may disrupt world provide chains, not directly affecting Indian element suppliers and electrical car ambitions.
Market Jitters Forward of Coverage Readability
Indian markets reacted swiftly, with pharma shares slipping almost 5 per cent in early commerce on February 19. Traders are on edge as they await additional readability on Trump’s commerce coverage. In the meantime, authorities officers in New Delhi are carefully monitoring the scenario. With the potential of Tesla’s entry into India and ongoing commerce negotiations, the approaching weeks will probably be essential in figuring out how India navigates this brewing tariff storm.
